Literature DB >> 16190176

Chronic open-angle glaucoma. Review for primary care physicians.

Feisal A Adatia1, Karim F Damji.   

Abstract

INTRODUCTION: Chronic open-angle glaucoma (COAG) is a leading cause of irreversible blindness worldwide, including in Canada. It presents a challenge in diagnosis, as disease often progresses without symptoms; an estimated 50% of cases are undetected. SOURCES OF INFORMATION: MEDLINE searches, reference lists of articles, and expert knowledge from one of the authors (K.F.D.), a glaucoma specialist, were used. MAIN MESSAGE: A casefinding approach using early referral to optometrists and ophthalmologists for early detection of COAG is helpful for patients with risk factors such as age above 50, a positive family history, black race, and myopia. Moderate evidence for referral also exists for the following risk factors: hypertension, type 2 diabetes mellitus, hypothyroidism, and sleep apnea. Treatment with intraocular pressure-lowering medication can arrest or slow the course of the disease, permitting patients to retain good visual function. Family physicians should be aware that some intraocular pressure-lowering medications, particularly topical beta-blockers, can pose iatrogenic harm to patients and result in or exacerbate such conditions as asthma, cardiovascular disturbances, depression, and sexual dysfunction.
CONCLUSION: Appropriate referral patterns and an understanding of common as well as serious side effects of glaucoma medications are important in optimizing management of patients at risk of developing, or who have, COAG.

Entities:  

Mesh:

Year:  2005        PMID: 16190176      PMCID: PMC1479464     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  31 in total

Review 1.  Target pressure in glaucoma therapy.

Authors:  H D Jampel
Journal:  J Glaucoma       Date:  1997-04       Impact factor: 2.503

2.  Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery.

Authors:  P R Lichter; D C Musch; B W Gillespie; K E Guire; N K Janz; P A Wren; R P Mills
Journal:  Ophthalmology       Date:  2001-11       Impact factor: 12.079

Review 3.  Comparison of the ocular beta-blockers.

Authors:  S J Sorensen; S R Abel
Journal:  Ann Pharmacother       Date:  1996-01       Impact factor: 3.154

4.  Influence of glaucomatous visual field loss on health-related quality of life.

Authors:  P Gutierrez; M R Wilson; C Johnson; M Gordon; G A Cioffi; R Ritch; M Sherwood; K Meng; C M Mangione
Journal:  Arch Ophthalmol       Date:  1997-06

5.  The cost-effectiveness of various modes of screening for primary open angle glaucoma.

Authors:  M W Tuck; R P Crick
Journal:  Ophthalmic Epidemiol       Date:  1997-03       Impact factor: 1.648

6.  The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.

Authors:  Mae O Gordon; Julia A Beiser; James D Brandt; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Michael A Kass
Journal:  Arch Ophthalmol       Date:  2002-06

7.  Cost effectiveness of screening for primary open angle glaucoma.

Authors:  J F Boivin; M McGregor; C Archer
Journal:  J Med Screen       Date:  1996       Impact factor: 2.136

8.  Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey.

Authors:  A Sommer; J M Tielsch; J Katz; H A Quigley; J D Gottsch; J Javitt; K Singh
Journal:  Arch Ophthalmol       Date:  1991-08

9.  Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey.

Authors:  J M Tielsch; J Katz; A Sommer; H A Quigley; J C Javitt
Journal:  Arch Ophthalmol       Date:  1994-01

10.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.

Authors:  Anders Heijl; M Cristina Leske; Bo Bengtsson; Leslie Hyman; Boel Bengtsson; Mohamed Hussein
Journal:  Arch Ophthalmol       Date:  2002-10
View more
  10 in total

Review 1.  Glaucoma: recent advances in the involvement of autoimmunity.

Authors:  Maria Ida Rizzo; Antonio Greco; Armando De Virgilio; Andrea Gallo; Luciano Taverniti; Massimo Fusconi; Michela Conte; Giulio Pagliuca; Rosaria Turchetta; Marco de Vincentiis
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  Bimatoprost 0.01 % for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting.

Authors:  Michael Scott Kook; Susan Simonyi; Yong Ho Sohn; Chan Yun Kim; Ki Ho Park
Journal:  Jpn J Ophthalmol       Date:  2015-07-23       Impact factor: 2.447

3.  Primary open-angle glaucoma and serum lipids.

Authors:  Suzana Pavljasević; Mensura Asćerić
Journal:  Bosn J Basic Med Sci       Date:  2009-02       Impact factor: 3.363

4.  Tolerability and effectiveness of preservative-free dorzolamide-timolol (preservative-free COSOPT) in patients with open-angle glaucoma or ocular hypertension.

Authors:  Cindy Hutnik; David Neima; Fahim Ibrahim; Robert Scott; Julie Vaillancourt; Denis Haine; John S Sampalis; Natacha Bastien; Sylvain Foucart
Journal:  Clin Ophthalmol       Date:  2010-07-21

5.  Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients.

Authors:  M Francesca Cordeiro; Ivan Goldberg; Rhett Schiffman; Paula Bernstein; Marina Bejanian
Journal:  Clin Ophthalmol       Date:  2015-08-31

6.  Primary care physicians' role perception and self-reported performance in glaucoma care: a survey study.

Authors:  Albina Rotshtein; Khaled Karkabi; Orna Geyer; Orit Cohen Castel
Journal:  BMC Res Notes       Date:  2015-12-12

7.  Patterns of care for glaucoma patients in Korea from 2002 to 2013 using the national health insurance service claims data.

Authors:  Seulggie Choi; Jin A Choi; Jin Woo Kwon; Sang Min Park; Donghyun Jee
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

8.  There's Danger in the Drops: Systemic Effects of Ophthalmic Drops Used to Treat Glaucoma.

Authors:  Claire Haga; Thomas Waller; Abhimanyu S Ahuja; Bryan Farford; Nancy Dawson; Mingyuan Yin
Journal:  Cureus       Date:  2022-01-04

9.  A Masked, Randomized, Phase 3 Comparison of Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol versus Fixed-Combination Brimonidine/Timolol for Lowering Intraocular Pressure.

Authors:  Curt Hartleben; Juan Camilo Parra; Amy Batoosingh; Paula Bernstein; Margot Goodkin
Journal:  J Ophthalmol       Date:  2017-09-19       Impact factor: 1.909

10.  Health insurance enrollment and vision health in rural China: an epidemiological survey.

Authors:  Xiaochang Yan; Baoqun Yao; Xi Chen; Shaoye Bo; Xuezheng Qin; Hua Yan
Journal:  BMC Health Serv Res       Date:  2021-07-31       Impact factor: 2.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.